
CLAIMS

1. Use of a mutant IDH1 enzyme inhibitor in the manufacture of a medicament for the treatment of a brain tumor, wherein the IDH1 enzyme inhibitor is for use in combination with temozolomide, wherein the brain tumor is a brain tumor to which temozolomide is effective, and wherein the IDH1 enzyme inhibitor is a compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I)

2. The use according to claim 1, wherein the mutant IDH1 enzyme inhibitor is a tert-butylamine salt of the compound of Formula (I).

3. The use according to claim 1 or 2, wherein the mutant IDH1 enzyme inhibitor and temozolomide are for administration simultaneously.

4. The use according to claim 1 or 2, wherein the mutant IDH1 enzyme inhibitor and temozolomide are for administration at different times.

5. The use according to claim 1 or 2, wherein the brain tumor is a brain tumor having an IDH1 gene mutation.


6. The use according to claim 5, wherein the IDH1 gene mutation is R132H, R132C, R132L, R132S, R132G, or R132V.

7. The use according to claim 5, wherein the IDH1 gene mutation is R132H mutation.

8. The use according to claim 5, wherein the IDH1 gene mutation is R132C mutation.

9. The use according to claim 1 or 2, wherein the brain tumor is a glioma.

10. Use of a mutant IDH1 enzyme inhibitor in the manufacture of a medicament for the treatment of a brain tumor, wherein the IDH1 enzyme inhibitor is for use in combination with temozolomide, wherein the dosage of temozolomide is effective in treating the brain tumor, and wherein the IDH1 enzyme inhibitor is a compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I)

11. The use according to claim 10, wherein the mutant IDH1 enzyme inhibitor is a tert-butylamine salt of the compound of Formula (I).

12. The use according to claim 10 or 11, wherein the mutant IDH1 enzyme inhibitor and temozolomide are for administration simultaneously.

13. The use according to claim 10 or 11, wherein the mutant IDH1 enzyme inhibitor

and temozolomide are for administration at different times.

14. The use according to claim 10 or 11, wherein the brain tumor is a brain tumor having an IDH1 gene mutation.

15. The use according to claim 14, wherein the IDH1 gene mutation is R132H, R132C, R132L, R132S, R132G, or R132V.

16. The use according to claim 14, wherein the IDH1 gene mutation is R132H mutation.

17. The use according to claim 14, wherein the IDH1 gene mutation is R132C mutation.

18. The use according to claim 14, wherein the brain tumor is a glioma.